Non Invasive Prenatal Testing (NIPT) Market by Product (Consumables, Reagent, Ultrasound, NGS, PCR, Microarray), Services, Method (cfDNA, Biochemical Markers), Application (Aneuploidy, Microdeletion) & End-User (Hospital, Labs)-Global Forecasts to 2024

“Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age.”
The non-invasive prenatal testing market is projected to reach USD 7.3 billion by 2024 from USD 3.9 billion in 2019, at a CAGR of 13.5% during the forecast period. Growth in this market is driven by the high risk of chromosomal abnormalities with increasing maternal age, growing preference for non-invasive techniques over invasive methods, improving reimbursement scenario for NIPT, and increasing awareness of NIPT. However, a dearth of skilled professionals is restraining the growth of this market.

“The services segment is expected to grow at the highest CAGR during the forecast period.”

Based on product and service, the NIPT market is segmented into products and services. The services segment is estimated to register the highest growth rate during the forecast period. The rising incidence of genetic disorders, increasing focus on prenatal screening, and government initiatives to provide prenatal testing services are contributing to the growth of this market.

“The diagnostic laboratories segment accounted for the largest share of the NIPT products market in 2018.”

Based on end user, the NIPT products market is classified into diagnostic laboratories and hospitals. In 2018, diagnostic laboratories formed the largest and fastest-growing end users of NIPT products. This can primarily be attributed to factors such as the implementation of initiatives by diagnostic laboratories to provide safe and effective prenatal tests and rising incidence of chromosomal abnormalities.

“Asia to witness high growth during the forecast period.”

By region, the global NIPT market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2018, North America accounted for the largest market share, followed by Europe. On the other hand, Asia is expected to grow at the highest CAGR during the forecast period. The developing healthcare infrastructure, rising awareness programs & conferences, and rising focus of prominent players on expanding their presence in Asia are driving market growth in this region.



The primary interviews conducted for this report can be categorized as follows:

‧ By Company Type: Tier 1 (32%), Tier 2 (44%), and Tier 3 (24%)
‧ By Designation: C-level (30%), D-level (34%), and Others (36%)
‧ By Region: North America (40%), Europe (28%), Asia (20%), and RoW (12%)

List of Companies Profiled in the Report

‧ Illumina, Inc. (US)
‧ Thermo Fisher Scientific Inc. (US)
‧ GE Healthcare (US)
‧ BGI (China)
‧ Agilent Technologies, Inc. (US)
‧ F. Hoffmann-La Roche Ltd. (Switzerland)
‧ PerkinElmer Inc. (US)
‧ Laboratory Corporation of America Holdings (LabCorp) (US)
‧ Natera, Inc. (US)
‧ Yourgene Health (UK)

Research Coverage:
This report provides a picture of the global NIPT market. It aims at estimating the size and future growth potential of the market across different segments, such as product & service, application, and region. The NIPT products market is segmented on the basis of method and end user. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall NIPT market and its subsegments. This report will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on the key market drivers, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 17
1.3.1 MARKETS COVERED 17
1.3.2 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 18
1.5 LIMITATIONS 18
1.6 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH DATA 19
2.1.1 SECONDARY SOURCES 20
2.1.1.1 Key data from secondary sources 20
2.1.2 PRIMARY SOURCES 21
2.1.2.1 Key data from primary sources 21
2.1.2.2 Key industry insights 22
2.2 MARKET SIZE ESTIMATION 23
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 25
2.4 MARKET SHARE ESTIMATION 25
2.5 ASSUMPTIONS FOR THE STUDY 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 31
4.1 NON-INVASIVE PRENATAL TESTING: MARKET OVERVIEW 31
4.2 NON-INVASIVE PRENATAL TESTING MARKET, BY APPLICATION (2019–2024) 31
4.3 NON-INVASIVE PRENATAL TESTING MARKET SHARE, BY METHOD & REGION (2018) 32
4.4 NON-INVASIVE PRENATAL TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 33
5 MARKET OVERVIEW 34
5.1 INTRODUCTION 34
5.1.1 DRIVERS 35
5.1.1.1 High risk of chromosomal abnormalities with increasing
maternal age 35
5.1.1.2 Growing preference for noninvasive techniques over
invasive methods 36
5.1.1.3 Improving reimbursement scenario for NIPT 37
5.1.1.4 Programs focusing on increasing the awareness of NIPT 37
5.1.2 OPPORTUNITIES 38
5.1.2.1 Untapped emerging markets 38
5.1.3 CHALLENGES 39
5.1.3.1 Reliability of test results, especially in obese women 39
5.1.3.2 Lack of skilled professionals 39
6 NON-INVASIVE PRENATAL TESTING MARKET, BY PRODUCT & SERVICE 40
6.1 INTRODUCTION 41
6.2 PRODUCTS 41
6.2.1 CONSUMABLES 42
6.2.1.1 Assay kits & reagents 44
6.2.1.1.1 North America is the largest market for assay kits & reagents segments 44
6.2.1.2 Disposables 45
6.2.1.2.1 Use of disposables to avoid contamination is one of
the major growth factors for this segment 45
6.2.2 INSTRUMENTS 45
6.2.2.1 Ultrasound devices 48
6.2.2.1.1 Popularity of ultrasound in fetal and embryonic imaging and safety has driven market growth 48
6.2.2.2 Next-generation sequencing systems 48
6.2.2.2.1 NGS systems have found rising use in NIPT 48
6.2.2.3 Polymerase chain reaction instruments 49
6.2.2.3.1 Increasing research in the field of prenatal genetic testing is expected to boost market growth 49
6.2.2.4 Microarrays 50
6.2.2.4.1 Flexibility of chips and short processing times have supported the use of microarrays 50
6.2.2.5 Other instruments 51
6.3 SERVICES 51
6.3.1 NORTH AMERICA SHOWS THE HIGHEST DEMAND FOR TESTING SERVICES 51
7 NON-INVASIVE PRENATAL TESTING PRODUCTS MARKET, BY METHOD 53
7.1 INTRODUCTION 54
7.2 ULTRASOUND DETECTION 54
7.2.1 ULTRASOUND DETECTION SEGMENT DOMINATES
THE NIPT PRODUCTS MARKET 54
7.3 BIOCHEMICAL SCREENING TESTS 56
7.3.1 HIGH INCIDENCE OF GENETIC DISORDERS & INCREASING FOCUS ON PRENATAL TESTING TO SUPPORT MARKET GROWTH 56
7.4 CELL-FREE DNA IN MATERNAL PLASMA TESTS 58
7.4.1 CELL-FREE DNA IN MATERNAL PLASMA TESTS SEGMENT TO REGISTER
THE HIGHEST CAGR IN THE FORECAST PERIOD 58
?
8 NON-INVASIVE PRENATAL TESTING MARKET, BY APPLICATION 61
8.1 INTRODUCTION 62
8.2 TRISOMY 62
8.2.1 TRISOMY FORMS THE LARGEST AND FASTEST-GROWING APPLICATION SEGMENT OF THE NIPT MARKET 62
8.3 MICRODELETION SYNDROME 64
8.3.1 HIGH INCIDENCE OF MICRODELETION SYNDROME IS A KEY FACTOR DRIVING THE GROWTH OF THIS APPLICATION SEGMENT 64
8.4 OTHER APPLICATIONS 66
9 NON-INVASIVE PRENATAL TESTING PRODUCTS MARKET, BY END USER 68
9.1 INTRODUCTION 69
9.2 DIAGNOSTIC LABORATORIES 69
9.2.1 INCREASE IN RESEARCH INTENSITY TO DRIVE THE USAGE OF NIPT PRODUCTS AMONG DIAGNOSTIC LABS 69
9.3 HOSPITALS 71
9.3.1 NORTH AMERICA HOLDS THE MAJOR SHARE OF THIS END-USER SEGMENT 71
10 NON-INVASIVE PRENATAL TESTING MARKET, BY REGION 74
10.1 INTRODUCTION 75
10.2 NORTH AMERICA 75
10.2.1 US 79
10.2.1.1 High number of babies born with chromosomal syndromes is a major factor driving the demand for non-invasive prenatal testing in the US 79
10.2.2 CANADA 81
10.2.2.1 Unfavorable reimbursement scenario for non-invasive prenatal testing is a key challenge for market growth in Canada 81
10.3 EUROPE 84
10.3.1 FRANCE 88
10.3.1.1 Favorable insurance coverage for prenatal testing to increase the adoption of NIPT in France 88
10.3.2 UK 90
10.3.2.1 High incidence of genetic abnormalities to increase the demand for prenatal testing procedures in the UK 90
10.3.3 GERMANY 92
10.3.3.1 Increasing healthcare spending—a major factor contributing to market growth in Germany 92
10.3.4 REST OF EUROPE 94
10.4 ASIA 96
10.4.1 HIGH COST OF NIPT PRODUCTS IS A MAJOR FACTOR LIMITING MARKET GROWTH IN ASIA DURING THE FORECAST PERIOD 96
10.5 REST OF THE WORLD 100
?
11 COMPETITIVE LANDSCAPE 104
11.1 OVERVIEW 104
11.2 MARKET PLAYER RANKING 105
11.3 COMPETITIVE LEADERSHIP MAPPING – PRODUCT MARKET 106
11.3.1 VISIONARY LEADERS 106
11.3.2 INNOVATORS 106
11.3.3 DYNAMIC DIFFERENTIATORS 106
11.3.4 EMERGING PLAYERS 106
11.4 COMPETITIVE SITUATION AND TRENDS 108
11.4.1 PRODUCT & SERVICES LAUNCHES 108
11.4.2 EXPANSIONS 109
11.4.3 ACQUISITIONS 110
11.4.4 OTHER STRATEGIES 111
12 COMPANY PROFILE 112
(Business Overview, Products and Services Offered, Recent Developments, and MnM View)*
12.1 ILLUMINA, INC. 112
12.2 THERMO FISHER SCIENTIFIC, INC. 115
12.3 GE HEALTHCARE (A WHOLLY OWNED SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 118
12.4 PERKINELMER, INC. 120
12.5 AGILENT TECHNOLOGIES, INC. 123
12.6 BEIJING GENOMICS INSTITUTE 125
12.7 F. HOFFMAN-LA ROCHE LTD. 127
12.8 LABORATORY CORPORATION OF AMERICA HOLDINGS 129
12.9 NATERA, INC. 132
12.10 YOURGENE HEALTH 134
* Business Overview, Products and Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
13 APPENDIX 137
13.1 DISCUSSION GUIDE 137
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 141
13.3 AVAILABLE CUSTOMIZATIONS 143
13.4 RELATED REPORTS 143
13.5 AUTHOR DETAILS 144